PNT Archives - BioTuesdays

Markets

Brookline starts POINT Biopharma at buy; PT $23

Brookline Capital Markets initiated coverage of POINT Biopharma (NASDAQ:PNT) with a “buy” rating and $23 price target. The stock closed at $8.07 on Nov. 30. POINT is a late-stage clinical oncology company focused on...

December 1, 2021

Developments

POINT Biopharma licenses Lu-177 production technology from Belgian Nuclear Research Center

POINT Biopharma Global (NASDAQ:PNT) entered into a technology license agreement with the Belgian Nuclear Research Center (SCK CEN) for Lu-177 purification technology to accelerate POINT’s in-house no-carrier-added...

November 24, 2021

Developments

POINT Biopharma, IONETIX in Ac-225 supply agreement

POINT Biopharma Global (NASDAQ:PNT) and IONETIX, a leading cyclotron technology and isotope manufacturing company, entered into a long-term supply agreement for actinium-225 (Ac-225) to support POINT’s validation, drug...

November 9, 2021

Developments

POINT Biopharma, Kinectrics in Yb-176 supply agreement for NA production of n.c.a. Lu-177

Radiopharmaceuticals developer, POINT Biopharma Global (NASDAQ:PNT), and Kinectrics entered into a long-term supply agreement for Ytterbium-176 (Yb-176) to support POINT’s in-house no-carrier added Lutetium-177 (n.c.a...

October 29, 2021

Executive Moves

Daniel Pearlstein joins POINT Biopharma in corporate strategy

Daniel Pearlstein was named associate director, corporate strategy, of POINT Biopharma (NASDAQ:PNT), which debuted on the Nasdaq Capital Market on July 1, 2021. Mr. Pearlstein was formerly EVP for...

September 27, 2021

Tag - PNT

Brookline starts POINT Biopharma at buy; PT $23

POINT Biopharma licenses Lu-177 production technology from Belgian Nuclear Research Center

POINT Biopharma, IONETIX in Ac-225 supply agreement

POINT Biopharma, Kinectrics in Yb-176 supply agreement for NA production of n.c.a. Lu-177

Daniel Pearlstein joins POINT Biopharma in corporate strategy

General

More

Sign up for the BioTuesdays weekly newsletter